Sean Wuxiong Cao - 18 Mar 2026 Form 3 Insider Report for NovaBridge Biosciences (NBP)

Role
Chief Business Development Officer and Director Exhibit List: Ex. 24.1 - Power of Attorney, Director
Signature
/s/ Xi-Yong (Sean) Fu as attorney-in-fact
Issuer symbol
NBP
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 21:37:45 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cao Sean Wuxiong Chief Business Development Officer and Director Exhibit List: Ex. 24.1 - Power of Attorney, Director C/O NOVABRIDGE BIOSCIENCES,, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE /s/ Xi-Yong (Sean) Fu as attorney-in-fact 18 Mar 2026 0002109966

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NBP Ordinary Shares 56,472 18 Mar 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NBP 2025 Employee Share Option (right to buy) 18 Mar 2026 Ordinary Shares 19,370 $1.17 Direct F1, F3, F4
holding NBP 2025 Employee Share Option (right to buy) 18 Mar 2026 Ordinary Shares 408,929 $4.65 Direct F1, F3, F5
holding NBP Restricted Share Units 18 Mar 2026 Ordinary Shares 408,933 Direct F1, F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
F2 Reported securities are represented by 24,553 ADSs.
F3 Number of underlying securities and exercise price expressed in terms of ADSs.
F4 The option was granted on May 28, 2025 and is vested and exercisable. Amount of underlying securities excludes a portion of the option that was forfeited upon the Reporting Person's appointment as an officer of the Issuer.
F5 The option was granted on September 3, 2025. The option vests and becomes exercisable, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADSs (based on trading days only) is at or above US$8.00.
F6 On September 3, 2025, the Reporting Person was granted 408,933 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.

Remarks:

Chief Business Development Officer and Director Exhibit List: Ex. 24.1 - Power of Attorney